Author:
Zheng P; Sun B
Author address:
Guangzhou Institute of Respiratory Diseases, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
Full conference title:
European Academy of Allergy and Clinical Immunology Congress 2017
Date: 20 August 2020
Abstract:
Introduction: ABPA is currently believed to be an exaggerated form of Aspergillus sensitization, and is probably the first step in its development.
Objectives: The aim of this study was to investigate the clinical and immunologic characteristics of fungal-sensitive asthma (FA), nonfungal-sensitive asthma(NFA) and ABPA.
Results: Prevalence of bronchiectasis (88.9%), as well as eosinophil number in sputum [13.0(1.5, 23.5)%], eosinophil number in blood [0.85(0.30, 1.41)*10^9/L], erythrocyte sedimentation rate [22(15, 40)] and dose of oral corticosteroid[15(10, 20)mg]) in the ABPA group was higher than that in the NFA group [20%; 3.5(1.5, 10.7) %; 0.14(0.01, 0.53)*10^9/L; 10(5, 35)mm/h; 10(0, 20) mg; P<.05]and FA group [25.6%; 11.5(6.5, 45.5) %; 0.15(0.00, 0.30) *10^9/L; 9(4, 17) mm/h; 10(0, 25) mg; P<.05].The FVC%pred [78.30(66.0, 89.0)%] and FEV1%pred [55.024.4%] in ABPA are significantly lower than those in NFA[89.3(78.7, 102.1)%; 70.224.0%; P<.05];Level of sIgE-M.x [4.63(0.97, 13.45)kU/L], sIgE-A.f [7.95(1.00, 26.13) kU/L], sIgG-A.f [82.5(22.7, 166.0) mgA/L] and total IgE [1332(1000, 3291) kU/L] in the ABPA group was higher than that in the FA group[0.66(0.45, 1.48) kU/L; 0.61(0.42, 2.80) kU/L; 18.3(7.6, 37.7)mgA/L; 992(293, 2123) kU/L]. sIgE-A.f. was negatively and linearly correlated with FVC% predicted, FEV1% predicted, PEF% predicted, and FEF25-75% predicted.
Conclusions: There were different clinical and immunological features among NFA, FA and ABPA. The ABPA had worse function as well as higher percentage of bronchiectasis, and higher dose of oral corticosteroid. Besides, the sensitivity to aspergillus was more severe in ABPA. The level of sIgE-A.f was associated with the damage of lung function.
Abstract Number: 0571
Link to conference website:
Link Conference abstract:
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
Teclegiorgis Gebremariam [MS]1, Yiyou Gu [PhD]1, Sondus Alkhazraji [PhD]1, Jousha Quran1, Laura K. Najvar [BS]2, Nathan P. Wiederhold [PharmD]2, Thomas F. Patterson [MD]2, Scott G. Filler [MD]1,3, David A. Angulo (MD)4, Ashraf S. Ibrahim [PhD]1,3*,
2024
91
n/a
-
v
Ruta Petraitiene (US)
2024
90
n/a
-
v
Fabio Palmieri (CH), Junier Pilar
2024
89
n/a
-
v
Evelyne Côté (CA)
2024
88
n/a
-
v
Eliane Vanhoffelen (BE)
2024
87
n/a
-
v
Teclegiorgis Gebremariam, Yiyou Gu, Eman Youssef, Sondus Alkhazraji, Joshua Quran, Nathan P. Wiederhold, Ashraf S. Ibrahim
2024
86
n/a
-
v
Thomas Orasch (DE)
2024
85
n/a
-
v
Julien Alex, Katherine González, Gauri Gangapurwala, Antje Vollrath, Zoltán Cseresnyés, Christine Weber, Justyna A. Czaplewska, Stephanie Hoeppener, Carl-Magnus Svensson, Thomas Orasch, Thorsten Heinekamp, Carlos Guerrero-Sánchez, Marc Thilo Figge, Ulrich S. Schubert, Axel A. Brakhage
2024
84
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
83
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
82
n/a